Lupin Limited — Updates, 15-05-2025: Press Release

Lupin has announced a board meeting to discuss the financial results for the quarter and half-year. The company secured U.S. FDA approval for its generic Rivaroxaban Tablets (10 mg, 15 mg, 20 mg), bioequivalent to Xarelto®, made at its Aurangabad plant. This approval opens access to a USD 8,052 million U.S. market in cardiovascular therapy, offering Lupin a strong growth avenue in stroke risk reduction and thromboprophylaxis treatments.